Experimental integrase inhibitor GSK-572 shows continued promise
Rilpivirine (TMC278) matches efavirenz in phase 3 studies, with fewer side-effects
Protease inhibitor to raltegravir switch maintains viral suppression, but NRTI resistance lowers efficacy
Low birth weight seen in small minority of infants exposed to some antiretroviral drugs
Children with HIV are at risk for metabolic problems and heart muscle dysfunction
TBR-652 blocks both CCR5 and CCR2, inhibiting HIV replication and reducing inflammation
Universal access to HIV treatment threatened by failure of will
Adolescents living with HIV face complex psychosocial concerns: require targeted, comprehensive services
